L3VLUP
ProSign in

MEDP · VRTX in the 13F filings

Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.

MEDPVRTX
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Holders over time

Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
  • MEDP
  • VRTX
010203040202120222023202420252026
Holders and value by quarter
QuarterMEDPVRTX
Q3 202012 holders, $218m31 holders, $21.9bn
Q4 20208 holders, $187m30 holders, $18.4bn
Q1 20219 holders, $153m31 holders, $15.4bn
Q2 20218 holders, $156m30 holders, $12.7bn
Q3 202111 holders, $413m35 holders, $10.1bn
Q4 202112 holders, $668m28 holders, $12.4bn
Q1 20226 holders, $107m23 holders, $16.1bn
Q2 20225 holders, $97m25 holders, $18.1bn
Q3 20223 holders, $59m22 holders, $18.4bn
Q4 202210 holders, $269m28 holders, $18.4bn
Q1 202314 holders, $275m26 holders, $21.4bn
Q2 202317 holders, $468m27 holders, $24.7bn
Q3 202315 holders, $378m33 holders, $24.3bn
Q4 202314 holders, $501m32 holders, $28.6bn
Q1 202417 holders, $1.2bn31 holders, $29.8bn
Q2 202418 holders, $1.3bn29 holders, $33.4bn
Q3 202415 holders, $918m27 holders, $33.5bn
Q4 202415 holders, $1.2bn26 holders, $28.5bn
Q1 202512 holders, $986m21 holders, $35.4bn
Q2 202514 holders, $1.2bn21 holders, $32.3bn
Q3 202517 holders, $1.9bn22 holders, $25.9bn
Q4 202514 holders, $2.1bn26 holders, $31.8bn
Q1 202612 holders, $1.8bn25 holders, $31.8bn
Q2 20269 holders, $2.7bn26 holders, $34.6bn
MEDP

Medpace HLDGS Inc

Holders
17
Reported value
$1.9bn
Buyers
9
Sellers
8

Breadth +1 among 95 comparable managers.

Health care services and researchHealthcare: biopharma and medtech · L3VLUP
VRTX

Vertex Pharmaceuticals Inc

Holders
22
Reported value
$25.9bn
Buyers
13
Sellers
10

Breadth +3 among 95 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations

Who holds both, Q3 2025

Among the 31 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.

Only MEDP (9)

AQR Capital Management LLC, Brevan Howard Capital Management LP, Caxton Associates LLP, D. E. Shaw & Co., PDT Partners LLC, Polen Capital Management LLC, Quantbot Technologies LP, Two Sigma Advisers LP, Two Sigma Investments LP

Only VRTX (14)

AllianceBernstein LP, ARK Investment Management LLC, Capital Research Global Investors, Capital World Investors, Fidelity (FMR LLC), Hudson Bay Capital Management LP, Invesco Ltd, MFS Investment Management, Neuberger Berman Group LLC, Squarepoint Ops LLC, T. Rowe Price Associates Inc, Tudor Investment Corp, Wellington Management Group LLP, Woodline Partners LP

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.

Back to the 13F Explorer →